Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Darazam, 2021
 
NCT04521400
RCThigh-dose IFN beta-1aIFN beta-1aCOVID 19 hospitalizedsome concern
83/85 inconclusive 19%
Li, 2021
 
ChiCTR2000029638
RCTrecombinant super-compound interferon rSIFN-coIFN alphaCOVID 19 hospitalizedsome concern
48/48 conclusif 4%
SOLIDARITY (interferon), 2020
 
NCT04315948
RCTIFN beta-1acontrolCOVID 19 hospitalizedsome concern
2063/2064 inconclusive 14% 4%
Synairgen SG016, 2020
 
NCT04385095
RCTSNG001 inhaled interferon betaplaceboCOVID 19 hospitalizedsome concern
50/51 suggested -75% 119% -56%

COVID 19 all comers meta-analysis

Cai -FAVIPIRAVIR, 2020
 
ChiCTR2000029600
NRainterferonlopinavir/ritonavirCOVID 19 all comersNA
35/45 suggested 493%
Cai -FAVIPIRAVIR, 2020
 
ChiCTR2000029600
NRainterferoninterferonCOVID 19 all comersNA
35/45 suggested 493%

COVID-19 mild to moderate meta-analysis

Fu, 2020
 
ChiCTR2000030262
RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
40/40 inconclusive 0%
Idelsis, 2020
 
RPCEC00000307
RCTIFN gammastandard of careCOVID-19 mild to moderatehigh
30/33 conclusif
Jagannathan, 2020
 
NCT04331899
RCTpeginterferonplaceboCOVID-19 mild to moderatesome concern
60/60 inconclusive

COVID-19 severe or critically meta-analysis

Darazam (COVIFERON Interferon beta-1a), 2021
 
NCT04343768
RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
20/20 suggested -63%
Darazam (COVIFERON Interferon beta-1b), 2021
 
NCT04343768
RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive -43%
Davoudi-Monfared, 2020
 
IRCT20100228003449N2
RCTIFN beta-1astandard of careCOVID-19 severe or criticallyhigh
46/46 suggested -63%
Rahmani, 2020
 
IRCT20100228003449N2
RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
40/40 conclusif -64%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).